|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
adults 18 years and older
|
|
gptkbp:alsoKnownAs
|
gptkb:Convidecia
gptkb:Ad5-nCoV
|
|
gptkbp:antigen
|
gptkb:SARS-CoV-2_spike_protein
|
|
gptkbp:approvedBy
|
gptkb:China
2021-02-25
|
|
gptkbp:boosterUse
|
approved in some countries
|
|
gptkbp:developedBy
|
gptkb:CanSino_Biologics
gptkb:Beijing_Institute_of_Biotechnology
|
|
gptkbp:dosesRequired
|
1
|
|
gptkbp:efficacyAgainstSevereCOVID19
|
~90%
|
|
gptkbp:efficacyAgainstSymptomaticCOVID19
|
~65%
|
|
gptkbp:emergencyServices
|
gptkb:Argentina
gptkb:Chile
gptkb:China
gptkb:Ecuador
gptkb:Hungary
gptkb:Indonesia
gptkb:Malaysia
gptkb:Mexico
gptkb:Pakistan
gptkb:Uzbekistan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CanSino COVID-19 vaccine
|
|
gptkbp:phase3TrialLocation
|
gptkb:Argentina
gptkb:Chile
gptkb:China
gptkb:Mexico
gptkb:Pakistan
gptkb:Russia
gptkb:Saudi_Arabia
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
nausea
diarrhea
fatigue
headache
loss of appetite
joint pain
muscle pain
cough
chills
pain at injection site
|
|
gptkbp:singleDose
|
yes
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:technology
|
non-replicating viral vector
|
|
gptkbp:vaccineType
|
viral vector vaccine
|
|
gptkbp:vectorFor
|
gptkb:adenovirus_type_5
|
|
gptkbp:WHOStatus
|
under assessment
|
|
gptkbp:bfsParent
|
gptkb:COVID-19
|
|
gptkbp:bfsLayer
|
4
|